Puma Biotechnology | PBYI - Operating Expenses

Stock Price
6.62
Daily Change
0.01 0.12%
Monthly
5.38%
Yearly
137.20%
Q1 Forecast
5.65

Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Incyte USD 1.12B 3.53B Dec/2025
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.28B 232M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025